Abstract
Purpose. To assess the response rate, survival, and toxicity of Taxol®(paclitaxel) as 1‐h infusion plus doxorubicin as first‐line treatment for patients with metastatic breast cancer (MBC).
Patients and methods. Seventy‐six patients with untreated MBC were recruited. All of them had measurable disease and were evaluable for toxicity. Fifty‐five percent of the patients had visceral involvement. The dose of doxorubicin was fixed at 50 mg/m2 as a short intravenous infusion, followed by 200 mg/m2 of Taxol as a 1‐h intravenous infusion. Doxorubicin was administered during the first seven cycles, continuing with Taxol only up to a maximum of ten cycles.
Results. Neutropenia was the most important toxicity: 30% grade 3 and 18% grade 4. Only 2 patients showed a decrease in the left ventricular ejection fraction (LVEF) which caused discontinuing the treatment. No clinical congestive heart failure (CHF) was observed. Seventy‐four patients were eligible for response evaluation: 10 (14%) achieved complete response (CR) and 46 (62%) achieved partial response (PR). The mean duration of response was 13.47± 1.35 months (95% confidence interval (CI): 10.82; 16.12) and the mean survival was 21.50± 1.42 months (95% CI: 18.72; 24.29).
Conclusion. The overall response (OR) rate was 76%. No CHF was assessed and 2 patients stopped treatment due to LVEF decrease. Although doxorubicin 50 mg/m2 followed by Taxol 200 mg/m2 in 1‐h intravenous infusion presents a toxicity profile which demands a close follow‐up, it represents a convenient outpatient schedule with similar activity rate compared to longer Taxol infusions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rowinsky EK, McGuire WP, Donehower RC: The current status of Taxol. Principles and practice of Gynecologic Oncology Updates. 1: 1–16, 1993
Holmes FA, Walters RS, Theriault RL, Forinan AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J NatI Cancer Inst 83: 1797–1805, 1991
Reichman BS, Seidman AD, Crown JPA, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A, Curie V, Hudis CA, Klecker R, Jamis-Dow C, Collins J, Quinlivan S, Berkery R, Toomasi F, Canetta R, Fisherman J, Arbuck S, Norton L: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. Semin Oncol 11: 1943–1951, 1993
Seidman AD, Norton L, Reichman BS, Crown JP, Heelan R, Hakes TB, Lebwolh DE, Gilewski TA, Surbone A: Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer. Semin Oncol 20: 40–45, 1993
Anand A: Paclitaxel in doxorubicin-resistant metastatic breast cancer patients. J NatI Cancer Inst 87: 1642, 1995 (letter)
Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ, Fraschini G, Buzdar AU, Frye D, Gibbs HR, Hortobagyi GN: The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. Monogr Natl Cancer Inst 15: 161–169, 1993
Sledge GW Jr, Robert N, Sparano JA, Cobleigh M, Goldstein LJ, Neuberg D, Rowinsky E, Baughman C, McCaskill-Stevens W: Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer. Semin Oncol 21: 15–18, 1994 (Suppl 8)
Conte PF, Baldini E, Gennari A, Michelotti A, Salvadori B, Tibaldi C, Danesi R, Innocenti F, Gentile A, Dell, Anna R, Ombretta B, Mariani M, Del Tacca M: Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: A regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol 15: 2510–2517, 1997
Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C, Stefanelli M, Valagussa P, Bonadonna G: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688–2699, 1995
Fisherman JS, McCabe M, Noone M, Ognibene FP, Goldspiel B, Venzon DJ, Cowan KH, O'shaughnessy JA: Phase I study of Taxol, doxorubicin, plus granulocyte-colony stimulating factor in patients with metastatic breast cancer. Monogr Natl Cancer Inst 15: 189–194, 1993
Fisherman J, McCabe M, Hillig M, Goldspiel B, Cowan KH, O'shaughnessy JA: Phase I study of Taxol and doxorubicin with G-CSF in previously untreated metastatic breast cancer. Proc Am Soc Clin Oncol 11: 57, 1992 (abstr. 54)
Fisherman JS, Cowan KH, Noone M, Denicoff A, Berg S, Poplack D, Balis F, Venzon D, McCabe M, Goldspiel B, Chow C, Ognibene FP, O'shaughnessy J: Phase I/Il study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer. J Clin Oncol 14: 774–782, 1996
Holmes FA, Madden T, Newman RA, Valero V, Theriault RL, Fraschini G, Walters RS, Booser DJ, Buzdar AU, Willey J, Hortobagyi GN: Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a Phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. Clin Oncol 14: 2713–2721, 1996
Kris MG, O'Connell JP, Gralla RJ, Wertheim MS, Parente RM, Schiff PB, Young CW: Phase I trial of Taxol given as a 3-hour infusion every 21 days. Cancer Treat Rep 70: 605–607, 1986
Grem JL, Tutsch KD, Simon KJ, Alberti DB, Willson JKV, Tormey DC, Swaminathan S, Trump DL: Phase I study of Taxol administered as a short intravenous infusion daily for 5 days. Cancer Treat Rep 71: 1179–1184, 1987
Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR, Van Echo DA, Von Hoff DD, Leyland-Jones B: Hypersensitivity reactions from Taxol. J Clin Oncol 8: 1263–1268, 1990
Swenerton K, Eisenhauer E, ten Bokkel Huinink W: Taxol in relapsed ovarian cancer: High versus low dose and short versus long infusion. Proc Am Soc Clin Oncol 12: 265, 1993 (abstr.)
Von Hoff DD, Layard NW, Basa P, Davis HL Jr, Von Hoff AD, Rozencweig M, Muggia FM: Risk factors for doxorubicininduced congestive heart failure. Ann Intern Med 91: 710–717, 1979
Madden T, Newman BA, Van NT: Sequence-dependent synergy of paclitaxel and doxorubicin in human breast carcinoma cells. Proc Am Assoc Cancer Res 36: 359, 1995 (abstr. 2139)
Webster LK, Millward MJ, Cosson EJ, Stokes KH, MacCallum KHP: Cremophor EL changes the pharmacokinetics of loxorubicin. Proc Am Assoc Cancer Res 36: 373, 1995 (abstr. 2221)
Rowinsky EK: Clinical pharmacology of Taxol. Monogr Natl Cancer Inst 15: 25–37, 1993
Gianni L: Theoretical and practical aspects of paclitaxel scheduling. Ann Oncol 6: 861–863, 1995 (editorial)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pazos, C., Mickiewicz, E., Di Notto, M.R. et al. Phase II of doxorubicin/taxol in metastatic breast cancer. Breast Cancer Res Treat 55, 91–96 (1999). https://doi.org/10.1023/A:1006194909859
Issue Date:
DOI: https://doi.org/10.1023/A:1006194909859